Deakin University
Browse

File(s) under permanent embargo

Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers

Version 2 2024-06-13, 09:08
Version 1 2015-03-17, 12:21
journal contribution
posted on 1999-02-01, 00:00 authored by D L Scarcella, C W Chow, M F Gonzales, C Economou, F Brasseur, David Ashley
The mRNA expression of the tumor-associated antigens MAGE and GAGE was examined in 60 high-grade brain tumors. This analysis was performed by using reverse transcription-PCR, Southern blotting, and sequencing. It was demonstrated that, of the eight GAGE genes, GAGE-2 and -7 were expressed in five of seven normal brains. Four groups of tumors--adult glioblastoma multiforme (n = 20), pediatric glioblastoma multiforme (n = 9), medulloblastomas (n = 15), and ependymomas (n = 14)--were analyzed for mRNA expression. The following frequencies were observed: MAGE-1, 0, 0, 13, and 0%, respectively; MAGE-2, 5, 11, 60, and 57%; MAGE-3 & -6, 0, 0, 13, and 0%; GAGE-1, 65, 11, 13, and 43%; and GAGE-3-6 and -8: 75, 78, 47, and 93%, respectively. Two unclassified tumors expressed GAGE-3-6 and -8 only. The absence of GAGE-1 expression in normal brain, its relatively high frequency of expression in high-grade brain tumors, and its unique 3' sequence, suggest it may represent a useful target for specific immunotherapy. The detection method of reverse transcription-PCR and Southern blotting may also be useful for rapid screening of biopsy specimens both for diagnostic purposes and to determine a patient's eligibility for specific immunotherapy.

History

Journal

Clinical Cancer Research

Volume

5

Issue

2

Pagination

335 - 341

Publisher

American Association for Cancer Research

Location

Philadelphia, Pa.

ISSN

1078-0432

Language

eng

Publication classification

C1.1 Refereed article in a scholarly journal

Copyright notice

1999, American Association for Cancer Research